Adam Leckenby

Adam Leckenby has held a variety of research positions since 2014. Adam started their career as a Research Student at the University of Hull, where they studied the role of Endo180 (uPARAP) in the metastatic progression of primary prostate and breast cancer. In 2015, they moved to the Northern Institute for Cancer Research, Newcastle University, where they worked as a Research Student and conducted bioinformatics research on the cause and consequence of aneuploidy (chromosomal copy number abberations) in the haematological malignancies acute lymphoblastic leukaemia and multiple myeloma. In 2016, they joined AkzoNobel as a Research Scientist (Biologist), where they were responsible for conducting research to develop biocide-free fouling control coatings. From 2017 to 2021, Adam Leckenby worked as a Research Technician at Newcastle University, where they pursued their own research work and collaborated with numerous research associates on their projects. In 2021, they began working as a Scientist II at Mestag Therapeutics.

Adam Leckenby has a comprehensive education history. From 2012 to 2015, they attended the University of Hull and earned a Bachelor's Degree in Biomedical Science. Adam then went on to Newcastle University from 2015 to 2016, where they earned a Master's Degree in Medical Science. Finally, from 2018 to 2021, they attended Cardiff University / Prifysgol Caerdydd and earned a Doctor of Philosophy - PhD in Haematology.